Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 18/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 17/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.66 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.65 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.65 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7413835 | 0.88 | CYP11B2 (0.78) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12027311 | 0.86 | CYP11B2 (0.76) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9984894 | 0.85 | CYP11B2 (0.75) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL21960161 | 0.85 | CYP11B1 (0.73) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9984093 | 0.84 | CYP11B2 (0.73) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9986363 | 0.84 | CYP11B2 (0.73) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14848543 | 0.84 | CYP11B2 (0.73) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12027214 | 0.84 | CYP11B2 (0.73) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4509505 | 0.84 | CYP11B2 (0.72) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL11723032 | 0.82 | HSD17B1 (0.83) | CYP11B2CYP11B1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546392-B2 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | UNIVERSITAET DES SAARLANDES (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546392-B2 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | UNIVERSITAET DES SAARLANDES (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546392-B2 | 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases | UNIVERSITAET DES SAARLANDES (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | UNIVERSITAET DES SAARLANDES (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | UNIVERSITAET DES SAARLANDES (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | UNIVERSITAET DES SAARLANDES (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2131826-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008116920-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116920-A2 | 17BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204234-A1 | 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases | HSD17B1, HSD17B11, HSD17B2 | CYP11B2 36/4885CYP11B1 26/4885CYP1A2 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.